Drugs for Neglected Diseases initiative unveils new plan for neglected patients

September 08, 2015

[Basel, Switzerland - 7 September 2015] After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.

As part of its updated Business Plan for the period 2015-2023, DNDi remains committed to developing treatments for African sleeping sickness, leishmaniasis, and Chagas disease as well as filarial diseases and paediatric HIV. Having recently transferred its malaria activities to the Medicines for Malaria Venture (MMV), DNDi will soon be launching new research and development (R&D) projects for hepatitis C and mycetoma, two very different diseases that share, with other important global health issues such as anti-microbial resistance, one key challenge: the existing system of biomedical innovation has failed to deliver safe, effective, quality products that are affordable to poor populations.

'New threats are emerging at breakneck speed in today's rapidly changing global health R&D landscape', said Dr Bernard Pécoul, Executive Director of DNDi. 'DNDi will remain focused on reaching our treatment targets for the most neglected diseases, but we are now in a position to apply new R&D models, where patient needs drive drug development over profits, and where prices of drugs are delinked from the cost of their development,' he added.

The Business Plan 2015-2023 was elaborated through a 24-month process and in-depth consultation with DNDi's founding partners, governments, key stakeholders, and experts in global health research. It was approved by the Board of Directors in June 2015. The new plan emphasizes DNDi's commitment to addressing the needs of neglected patients, while allowing for more flexibility to extend the scope of diseases to address current and future unmet and/or urgent patient needs as they arise. A range of operating and support models has been designed to ensure DNDi's engagement is tailored and appropriate to the need.

For example, the high-cost of a new generation of drugs for hepatitis C has become one of the world's most pressing and high-profile public health challenges, leaving millions of patients behind. To develop an affordable public health tool for hepatitis C, DNDi will conduct clinical trials for combinations consisting of recently approved drugs and clinical-stage compounds in middle-income countries. For mycetoma, DNDi will test a promising drug candidate for this devastating illness for which there has been virtually no R&D - leaving patients to suffer with toxic and ineffective drugs. To help address the global threat posed by anti-microbial resistance, DNDi will create an internal task force, in collaboration with WHO, to assess the potential of an incubator to house a new initiative focused on developing antibiotics.

DNDi will continue developing its pipeline of over 30 projects for the most neglected diseases. By its 20th anniversary in 2023, DNDi aims to deliver 16 to 18 new treatments with an estimated total budget of EUR 650 million. Importantly, DNDi will use its own experience to forcefully advocate for a global R&D framework that guarantees both innovation and equitable patient access to health technologies.

'The Ebola crisis showed the world the need for highly effective collaborations and timely response,' said Professor Marcel Tanner, Chair of the Board of Directors, DNDi. 'As the organization matures, DNDi will continue to learn, innovate, and adapt its operational models to guarantee that R&D capacity is built where needed while continuously identifying and addressing neglected patients' needs through the best science.'
-end-
Short DNDi Business Plan video : https://youtu.be/tulpS871MwA

About the Drugs for Neglected Diseases initiative (DNDi)

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected diseases, in particular leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception in 2003, DNDi has delivered six treatments: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease. DNDi has established regional disease-specific platforms, which bring together partners in disease-endemic countries to strengthen existing clinical research capacity, as well as to build new capacity where necessary. http://www.dndi.org

Press Contacts

USA - Ilan Moss
imoss@dndi.org / +1 646 266 5216

India - Manisha Sharma
msharma@dndi.org / +91 9711 009 088

Europe - Gabrielle Landry
glandry@dndi.org / +41 79 309 3910

Africa - Linet Atieno Otieno
latieno@dndi.org / +25 473 362 4206

Drugs for Neglected Diseases Initiative

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.